United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the stock in a transaction on Wednesday, October 22nd. The stock was sold at an average price of $422.15, for a total value of $1,688,600.00. Following the sale, the chief executive officer owned 130 shares in the company, valued at approximately $54,879.50. This represents a 96.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $421.64 on Thursday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $459.48. The company has a market capitalization of $19.02 billion, a PE ratio of 16.46, a price-to-earnings-growth ratio of 4.60 and a beta of 0.66. The business’s fifty day moving average is $393.00 and its 200 day moving average is $330.45.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. During the same quarter last year, the business posted $5.85 EPS. The company’s quarterly revenue was up 11.7% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. grew its stake in shares of United Therapeutics by 31.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 9,179 shares of the biotechnology company’s stock valued at $2,830,000 after buying an additional 2,211 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its stake in shares of United Therapeutics by 17.9% during the first quarter. Robeco Institutional Asset Management B.V. now owns 226,287 shares of the biotechnology company’s stock valued at $69,757,000 after buying an additional 34,362 shares during the last quarter. Diversified Trust Co grew its stake in shares of United Therapeutics by 139.8% during the first quarter. Diversified Trust Co now owns 1,842 shares of the biotechnology company’s stock valued at $568,000 after buying an additional 1,074 shares during the last quarter. Achmea Investment Management B.V. grew its stake in shares of United Therapeutics by 61.1% during the first quarter. Achmea Investment Management B.V. now owns 59,180 shares of the biotechnology company’s stock valued at $18,243,000 after buying an additional 22,434 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock valued at $1,129,000 after buying an additional 376 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on UTHR shares. UBS Group increased their price objective on United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a research report on Monday, September 29th. Weiss Ratings reiterated a “hold (c+)” rating on shares of United Therapeutics in a research report on Wednesday, October 8th. Bank of America increased their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Morgan Stanley increased their price objective on United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a research report on Friday, October 10th. Finally, Cantor Fitzgerald increased their target price on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Nine analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $461.62.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.